Core Viewpoint - The "Implementation Plan for the Digital and Intelligent Transformation of the Pharmaceutical Industry (2025-2030)" aims to enhance the efficiency, quality, and innovation capabilities of the pharmaceutical industry through digital transformation and the application of technologies like artificial intelligence [1][2]. Group 1: Transformation Goals - By 2027, the plan targets breakthroughs in key technologies, the establishment of over 30 technical standards, and the development of more than 100 high-performance products in smart pharmaceutical equipment and software [2]. - The plan aims for full coverage of digital transformation among large-scale pharmaceutical enterprises by 2030 [2]. Group 2: Key Actions - The plan outlines four main action areas: empowering with digital technology, promoting digital transformation, building a supportive service system, and enhancing regulatory capabilities [3][4][5][6]. - Specific tasks include developing exemplary application scenarios, fostering leading enterprises, and establishing innovation platforms [2][6]. Group 3: Industry Impact - The digital transformation is expected to accelerate the entire pharmaceutical supply chain, improving collaboration and operational efficiency from raw material suppliers to healthcare institutions [7]. - AI-driven platforms are anticipated to significantly reduce drug development cycles and costs, facilitating faster market entry for new drugs [8][10]. Group 4: Traditional Medicine Modernization - The digital transformation will also support the modernization and internationalization of traditional Chinese medicine, enhancing its quality and consistency through automated production processes [8][10]. - AI technologies are being utilized to optimize traditional medicine formulations and predict new indications, thereby streamlining the research and development process [8][10].

Core Viewpoint - The "Implementation Plan for the Digital and Intelligent Transformation of the Pharmaceutical Industry (2025-2030)" aims for comprehensive digital transformation of large-scale pharmaceutical enterprises by 2030, enhancing competitiveness and ensuring drug quality and supply security [1][2] Group 1: Development Goals - By 2027, significant progress in digital transformation is expected, including breakthroughs in key technologies and the development of over 100 high-performance products in smart pharmaceutical equipment and software [1] - More than 100 intelligent pharmaceutical factories and over 10 innovation platforms for pharmaceutical models and technology applications are to be established by 2027 [1] - By 2030, large-scale pharmaceutical enterprises are expected to achieve full coverage of digital transformation, with enhanced innovation capabilities and a more complete data system across the pharmaceutical industry [1] Group 2: Specific Actions - The plan outlines 14 specific tasks focusing on four main areas: empowering actions through digital technology, promoting digital transformation, building a digital service system, and enhancing digital supervision [2] - It encourages collaboration among pharmaceutical companies, medical institutions, and research institutes to build a pharmaceutical big data platform for high-quality data collection across various fields [2] - The establishment of high-performance cloud computing platforms, blockchain, data centers, and other information infrastructure is encouraged to support the digital transformation of pharmaceutical enterprises [2] Group 3: Policy Support - The Ministry of Industry and Information Technology will strengthen policy coordination and increase support for the digital transformation of the pharmaceutical industry through national science and technology projects [2] - Local governments are encouraged to enhance resource support and promote cross-regional cooperation among pharmaceutical enterprises and their supply chains [2] - The plan also aims to align domestic and international regulations, standards, and technical exchanges in the field of pharmaceutical digitalization [2]

ETF Industry News Summary Core Insights - The ETF market is experiencing mixed performance, with several innovative drug-themed ETFs showing gains while others in the fintech sector are declining [1][2][5]. Market Performance - Major indices showed varied results, with the Shanghai Composite Index up by 0.03%, while the Shenzhen Component and ChiNext indices fell by 0.58% and 0.68%, respectively [5]. - The average position of newly listed stock ETFs in April is 17.05%, with the highest being 50.02% for the Bosera National Index Large Cap Value ETF [4]. Investment Trends - The Ministry of Industry and Information Technology has issued a plan for the digital transformation of the pharmaceutical industry, emphasizing AI applications and collaboration among leading pharmaceutical companies [2]. - Guotai Junan Securities highlights two key investment themes for 2025: the export of high-quality innovative drugs and the valuation recovery of left-side assets in the pharmaceutical sector [2]. ETF Holdings and Growth - As of the end of Q1 2025, public equity ETFs held a market value of 27,745.72 billion yuan, representing 3.78% of the A-share market's circulating value, a significant increase from 0.37% in June 2015 [3]. - The average fundraising for newly listed ETFs in April was 5.43 million shares, with the largest being the Ping An CSI A500 ETF at 20.27 million shares [4]. Sector Performance - The beauty care, banking, and public utilities sectors performed well today, while the computer, communication, and electronics sectors lagged [7]. - Among different ETF categories, commodity ETFs showed the best average performance with a gain of 0.80%, while cross-border ETFs had the worst performance with a decline of 0.78% [10]. Top Performing ETFs - The top-performing stock ETFs today included the Low Volatility 100 ETF, the CSI 2000 Enhanced ETF, and the Innovative Drug ETF, with gains of 1.81%, 1.57%, and 1.48%, respectively [12][13].

工信部等七部门：落实数据基础制度，推进医药工业公共数据规范化开发利用 金十数据4月24日讯，工信部等七部门关于印发《医药工业数智化转型实施方案（2025—2030年）》， 其中提到，鼓励医药企业、医疗机构、科研院所等合作建设医药工业大数据平台，形成研发、生产、临 床、大健康等领域高质量数据集，推进数据分类分级管理和数据要素市场试点。落实数据基础制度，推 进医药工业公共数据规范化开发利用，完善医药工业数据产权归属认定、市场交易、权益分配、利益保 护等具体规则，培育专业化医药数据服务企业，支持数据交易机构开展医药工业数据流通共享探索。推 动落实数据管理能力成熟度、个人信息保护等评估，规范医药工业数据跨境传输管理。 ...

Group 1 - The core viewpoint of the article emphasizes the strengthening of research and application of intelligent products in the pharmaceutical industry as outlined in the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)" issued by the Ministry of Industry and Information Technology and six other departments [1] - The plan includes organizing "challenge" initiatives for pharmaceutical digital solutions and technology products, targeting the production characteristics of various sub-sectors such as chemical drugs, traditional Chinese medicine, biological products, and medical devices [1] - The initiative aims to develop a series of intelligent pharmaceutical equipment and testing devices, as well as to create "small, fast, light, and precise" pharmaceutical industrial software or systems that comply with the Good Practice (GXP) quality management system [1]

金十数据4月24日讯，工信部等七部门关于印发《医药工业数智化转型实施方案（2025—2030年）》， 其中提到，统筹国家科技项目渠道加大对医药工业数智化转型的支持，落实首台（套）重大技术装备、 大规模设备更新、技术改造、软件产品等政策，优化审评前置等监管政策，支持医药工业数智技术、产 品的研发与推广应用。鼓励地方加强要素保障，统筹项目、融资、用地、用能等支持政策，促进医药企 业数智化建设重点项目尽快落地见效。发挥国家产融合作平台作用，引导金融机构为医药工业数智化转 型项目提供中长期贷款、供应链金融、融资租赁、上市辅导等金融服务。 工信部等七部门：引导金融机构为医药工业数智化转型项目提供中长期贷款、供应链金融、融资租赁、 上市辅导等金融服务 ...

Core Viewpoint - The Ministry of Industry and Information Technology, along with six other departments, has issued a notice regarding the implementation plan for the digital and intelligent transformation of the pharmaceutical industry from 2025 to 2030, aiming for significant advancements by 2027 in competitiveness and quality management across the entire pharmaceutical supply chain [1] Group 1 - By 2027, the pharmaceutical industry is expected to achieve important progress in digital and intelligent transformation [1] - The transformation will be driven by digital technologies, enhancing the competitiveness of the entire pharmaceutical industry chain [1] - There will be a notable improvement in lifecycle quality management levels within the pharmaceutical sector [1]